NHL Cyberfamily home
|
Selected Non-Hodgkin's Lymphoma abstracts from the
http://www.abstracts2view.com/hem07/ List compiled by |
See also the new 2010 ASH abstracts
CONTENTS
Recurrence, Secondary Neoplasia, and Late Complications after Transplantation
Clinical Results: Allogeneic Matched Related Donor Transplantation I
Experimental Transplantation: Basic Biology and Engraftment and Conditioning Regimens
Non-Hodgkin Lymphoma: Biology-Aggressive B Cell Non-Hodgkin Lymphoma
Recurrence, Second Cancer, and Late Complications after Transplantation
Clinical Care: Acute and Chronic GVHD Post Allogeneic Stem Cell Transplantation
Clinical Care: Transplantation Regimen Toxicities and Engraftment I
Clinical Results: Alternative Donor Transplantation-Umbilical Cord Blood Transplants
Experimental Transplantation: Pre-Clinical and Clinical Studies on GVHD/GVL
Non-Hodgkin Lymphoma: Biology-Indolent B Cell Non-Hodgkin Lymphoma
Lymphoma: Chemotherapy, excluding Pre-Clinical Models-Follicular and Mantle Cell Lymphoma
Clinical Results: Allogeneic Matched Related Donor Transplantation II
Lymphoma: Chemotherapy, excluding Pre-Clinical Models-Aggressive Lymphoma
Tumor Immunotherapy: Cancer Vaccines and Adoptive Immunotherapy in the Context of Transplantation
Clinical Care: Transplantation Regimen Toxicities and Engraftment-Regimen-Related Toxicities
Clinical Results: Allogeneic Matched Related Donor Transplantation II
Immuno-Chemotherapy for Diffuse Large B Cell and Follicular Lymphoma
Recurrence, Secondary Neoplasia, and Late Complications after Transplantation
[1082] The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma. [1084] Efficacy and Safety of Rituximab in Post Transplant Lymphoproliferative Disorders (PTLD): Pooled Analysis and Review of Literature.Clinical Results: Allogeneic Matched Related Donor Transplantation I 1086] The Dose of CD34+ Cells Negatively Impacts the Outcome of Patients Treated with Genoidentical Allo SCT Prepared with a Reduced Intensity Conditioning (RIC). [1088] Impact of FLT3 Internal Tandem Duplication (FLT3/ITD) on the Outcome of HLA-Identical Sibling Hematopoietic Transplantation for Adult Acute Myeloid Leukemia (AML) in First Remission: Substantial Probability of Leukemia-Free Survival Despite Increased Relapse Risk. A Retrospective Analysis of the EBMT-ALWP. [1090] Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Myeloid Leukemia (AML): Long Term Results of a “Donor” Versus “No Donor” Comparison. [1092] Allogeneic Stem Cell Transplantation Can Be an Effective Post-Remission Strategy for Acute Myeloid Leukemia Patients Aged Less Than 60 Years with Core Binding Factor: A Nation-Wide Retrospective Study in Korea. [1094] Should Hematopoietic Stem Cell Transplantation in First Complete Remission Be Restricted to High-Risk Patients in Childhood Acute Myeloid Leukemia? [1096] Imatinib Mesilate Versus Allogeneic Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia in First Chronic Phase – A Brazilian Point of View. [1098] Predictive Potential of Minimal Residual Disease Level after the First Imatinib Cycle on the Outcome of Allogeneic Stem Cell Transplantation in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. [1100] Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT).
[1101] Nasal Epithelial Cells of Donor Origin after Allogeneic HCT.
[1102] Early Recovery of Absolute Lymphocyte Count (ALC) Is a Predictor of Long-Term Outcome Following Related Allogeneic Peripheral Blood Stem Cell Transplantation in Adults with AML/MDS. [1104] Number of Prior Chemotherapy Regimens: Important Prognositic Factor of All-Cause Mortality after Allogeneic Hematopoietic Cell Transplantation. [1106] Bone Marrow Transplantation for β Thalassemia Major: Long Term Experience from a Single Centre in India. [1108] The Transfusion Iron Overload Score Is a Potential Predictor of Survival in Stem Cell Transplant Patients. [1110] Risk Factors and Outcome after Second HLA-Matched Sibling Donor Transplantation for Graft Failure after a First HLA-Matched Sibling Transplant in Severe Aplastic Anemia. [1112] Outcome of Hematopoietic Cell Transplantation in Children with Sickle Cell Disease, a Single Center's Experience.Experimental Transplantation: Basic Biology and Engraftment and Conditioning Regimens
[1186] Flt3-Ligand Plays a Critical Role in Restoring Function of NOD Facilitating Cells.
[1187] Fucosylation of Cord Blood CD34+ Cells Improves the Rate of Engraftment without Compromising Long-Term Engraftment. [1189] MHC-Matched Stem Cell Transplantation in Rhesus Macaques Using a Costimulation Blockade-Based Immunomodulation Platform. [1191] A Small Animal In Vivo Imaging Model of Expanded vs. Unexpanded UCB Stem Cells Reveals Differential Patterns of Engraftment. [1193] Intensive Supportive Care and Cytokines Promote Recovery of Hematopoiesis after Total Body Irradiation (TBI) without Hematopoietic Stem Cell Support.[1194] Low Dose Busulfan Produces Efficient Human Cell Engraftment in Immunodeficient Mice.
[1195] Expression of HLA-G1 and G5 Enables Human Mesenchymal Stem Cells To Engraft at High Levels across Xenogeneic Barriers Following Transplantation into Immunocompetent Recipients. [1197] A Novel Plant Mannose-Binding Lectin, NTL, Preserves Cord Blood Hematopoietic Stem/Progenitor Cells in Long-Term Culture and Enhances Their Ex Vivo Expansion. [1199] Exchange of microRNAs between Breast Cancer Cells and Bone Marrow Stroma: Potential for Avenues To Revisit Hematopoietic Stem Cell Transplantation for Breast and Other Cancers That Show Preference for Bone Marrow. [1201] Migration of Donor Cells from the Yolk Sac to Fetal Tissues after In Utero Transplantation of Early to Mid-Gestation Canine Fetuses.[1202] Encouragement of Transplacental Stem Cell Transplantation.
Immuno-Chemotherapy for Lymphoma
[1278] Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation ± Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). [1280] Rituximab Maintenance Following High Dose Therapy and Autologous Stem Cell Rescue after RICE Cytoreduction Improves Event Free and Overall Survival. [1282] Update of a GITIL Cohort Study: Frontline High Dose Sequential Chemotherapy with Rituximab and Autologous Stem Cell Transplantation Induces a High Rate of Long-Term Remissions in Patients with Mantle Cell Lymphoma. Session Type: Poster Session, Board #436-I - 05:30 PM [1284] Correlation of Peripheral Blood Involvement Measured by Four-Color Flow Cytometry and the Achievement of Molecular Response in Mantle Cell Lymphoma Treated within the Prospectively Randomized Intergroup Trials of the European MCL Network. [1286] Induction with Fludarabine, Cyclophosphamide and Rituximab as Front-Line Therapy Against Follicular Lymphoma: Results from a Cooperative Spanish Trial. [1288] Predictive Factors to Hypogammaglobulinemia and Non-Neutropenic Infection Complications after Rituximab/Chemotherapy Treatment. [1290] Fludarabine, Cyclophosphamide and Rituximab in Waldenström's Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results. [1292] Addition of Rituximab Improves Progression-Free and Overall Survival in Patients with B-Cell Lymphoma Receiving Doxorubicin-Containing Chemotherapy. [1294] Pre-Treatment p27 and Bcl-6 Staining Levels Correlate with Response to Bortezomib in Non-Hodgkin Lymphoma: Results from a Tissue Microarray Analysis. [1296] Early Results of a Phase II Trial Testing Low Dose Total Body Irradiation (LTBI) after Chemoimmunotherapy in Elderly High Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL). [1351] Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma. [1353] Treatment of Indolent Non-Hodgkin's Lymphoma in Germany – Results of a Representative Population-Based Survey. [1355] Pattern of Relapse in Localized Gastric Lymphoma Registered within the Prospective German Multicenter Study GIT NHL 01/92. [1357] Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom's Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.[1358] A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.
[1359] Persistent Monoclonality after Histological Remission in Gastric Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Treated with Chemotherapy and/or Surgery: Influence of t(11;18)(q21;q21). [1361] Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study. [1363] Phase-2 Study of R-MACLO-IVAM-T in Newly Diagnosed Mantle Cell Lymphoma. [1365] Primary Central Nervous System Lymphoma (PCNSL): Intent-to-Treat Analysis of Monocenter Long-Term Experience. [1367] Eighty-Five Cases of Lymphoma in a Solid Organ Transplant (SOT) Population: Risk, Treatment, and Histologic Subtype. [1369] Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity. [1371] A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies. [1373] Non-Hodgkin's Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.Non-Hodgkin Lymphoma: Biology-Aggressive B Cell Non-Hodgkin Lymphoma [1558] PTP1B, Distinctively Expressed in GCB-Like and ABC-Like DLBCL, Is a New Regulator of IL-4-STAT6 Intracellular Signaling. [1560] High Skp2 Expression Is an Independent Predictor of Unfavorable Outcome in 333 Patients with Diffuse Large B Cell Lymphoma (DLBCL). [1562] Regulation of Hox Genes by Polycomb Group Protein EZH2 Plays a Critical Role in Diffuse Large B-Cell Lymphoma Cells. [1564] De Novo CD5+ Diffuse Large B-Cell Lymphoma: Result of a Detail Morphologic Evaluation and Long-Term Follow Up of 128 Patients. Session Type: Poster Session, Board #718-I - 05:30 PM [1566] MicroRNAs Specific for Immune-Privileged Diffuse Large B-Cell Lymphoma.
[1567] Outcome of Diffuse Large B Cell Lymphoma in the United States: Review of SEER Data.
[1568] Polymorphisms in One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL). [1571] Inhibition of Ubiquitin-Proteasome Pathway Causes Growth Suppression and Induces Apoptosis in Diffuse Large B Cell Lymphoma. [1573] Expression of Phosphorylated mTOR (p-mTOR) Correlates with Advanced Stage in Diffuse Large B-Cell Lymphomas. [1575] Serum B-Cell Activating Factor (BAFF) in Diffuse Large B-Cell Lymphoma: Its Prognostic Significance in the Rituximab Era.[1576] CXCL12 and CXCL13 Levels in Cerebrospinal Fluid (CSF) of Patients with CNS Lymphoma.
[1577] Role of C-MYC Rearrangement in Survival Status of HIV Positive and HIV Negative Patients with Diffuse Large B-Cells Lymphoma. [1579] Clonal Heavy and Light Chain Immunoglobulin DNA in Plasma/Serum of AIDS Lymphoma Patients.[1580] Analysis of T-Cell Subpopulations in the Lymph Nodes of Patients with Mantle Cell Lymphoma.
[1581] Cyclin D1 Polymorphisms as Predictive and Prognostic Molecular Markers in 90 Mantle Cell Lymphoma Patients Treated with R-HyperCVAD. [1583] Signaling Pathways of All-Trans Retinoic Acid (ATRA)-Induced Apoptosis in Mantle Cell Lymphoma (MCL). [1585] SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.Recurrence, Second Cancer, and Late Complications after Transplantation
[1646] Clinical Trial of Therapeutic Blockade of CTLA4 with Ipilimumab in Patients with Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation. [1648] Effect of Interventions for Relapse or Progression Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience of 93 Patients. [1650] Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC). [1652] Donor Lymphocyte Infusion for Mixed Chimerism or Residual Disease after Reduced-Intensity T Cell Depleted Stem Cell Transplantation Results in Conversion to Full Donor Chimerism Combined with Graft Versus Tumor Responses and Limited GVHD. [1654] Factors Influencing Relapse after Allogeneic Hematopoietic Cell Transplantation (HCT) Following Reduced Intensity Conditioning (RIC) in Patients with AML and MDS. [1656] Myeloid Dyspoiesis as Determined by Flow Cytometry Is a More Powerful Predictor of Post-Transplant Relapse with MDS Than the Marrow Myeloblast Count. [1658] Analysis of 121 Allograft Recipients for the Treatment of Lymphoma: Progressive Disease by Functional and/or CT Imaging Is a Critical Determinant of Survival. [1660] Corticosteroid Therapy Does Not Increase Relapse Rate after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogeneous Leukemia and Myelodysplastic Syndrome Overt Leukemia. [1662] Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). [1664] No Difference in Survival or Long-Term Disease Outcomes in Palifermin-Treated Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation. [1666] Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.[1667] Burden of Illness in Chronic Graft vs. Host Disease – A Prospective Cohort Study.
[1668] Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation. [1670] High Incidence of Fatty Liver and Insulin Resistance in Long-Term Adult Survivors of Childhood Stem Cell Transplantation Recipients.[1671] Non-Relapse Mortality Associated with Autologous Stem Cell Transplant (ASCT).
[1672] The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation. [1674] Risk of Acute Leukemia Post-Autologous Stem Cell Tranplant (ASCT) for Hodgkin's Lymphoma (HL) Depends on Choice of Salvage Chemotherapy and Use of Radiation.Autologous Transplantation for Lymphoma I [20] Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment. [22] 90Yttrium Ibritumomab Tiuxetan (Zevalin) Combined with BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Follicular Lymphoma. GELA Phase II Study. [24] Comparable Survival between HIV+ and HIV- Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL) Patients Undergoing an Autologous Peripheral Blood Stem Cell Transplantation (ASCT). A Retrospective Analysis of the EBMT Lymphoma Working Party.
Clinical Care: Acute and Chronic GVHD Post Allogeneic Stem Cell Transplantation [38] A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease (GVHD) Predicts Long Term Survival.
[39] Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.
[40] Prophylaxis of Graft-Versus-Host Disease (GVHD) with Pentostatin, Tacrolimus, and "Mini"-Methotrexate (MTX): A Phase I/II Controlled, Randomized Study in Unrelated Donor (UD) Transplantation. [42] Prospective Evaluation of the NIH Staging Criteria in Chronic GVHD and Correlation to Quality of Life – Results of a German Multicenter Validation Trial.Diffuse Large B Cell Lymphoma: Prognosis [50] Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues. [52] LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras. [54] Prognostic Value of Tumor-Infiltrating TIA-1+ Cytotoxic T Cells (TIA1-CTCs) and FOXP3+ Regulatory T Cells (Tregs) in Post-Transplant Lymphoproliferative Disorder (PTLD) Following Solid Organ Transplant (SOT)
Novel Therapeutic Agents for Non-Hodgkin Lymphoma [122] Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study. [124] A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL). [126] Adoptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells (ACTC) Enhances Numeric and Functional Lymphocyte Recovery after Cyclophosphamide – Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma.
Autologous Transplantation for Lymphoma II [1888] Autologous Stem Cell Transplantation (ASCT) for Elderly Patients (≥ 60 Years) with Non-Hodgkin's Lymphoma (NHL): An Analysis Based on EBMT Registry. [1890] High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients. [1892] The Clinical Outcomes of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma: from Retrospective Multicenter Study in Korea. [1894] Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy.
[1895] Long Term Follow Up with Etoposide Priming in Patients with Lymphoma.
[1896] Clinical Outcomes of Patients with Recurrent/Refractory Hodgkin Disease Receiving Cyclosporine, Interferon-γ, and Interleukin-2 Immunotherapy To Induce Autoreactivity after Autologous Stem Cell Transplantation with BEAM: A COG Study. [1898] A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305). [1900] Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin's Lymphomas (NHLs). [1902] Prolonged Clinical and Molecular Remissions Following High-Dose Therapy/Autologous Stem Cell Transplantation (HDT/ASCT) and Rituximab and Interferon-alpha Maintenance for Relapsed High-Risk Follicular Lymphoma. [1904] The Impact of Histological Subtypes on Outcome in Patients with Mantle Cell Lymphoma Treated with or without Autologous Stem Cell Transplant. [1906] Long Term Results of Autologous Hematopoietic Cell Transplantation (AHCT) for Peripheral T Cell Lymphoma: The Stanford Experience. [1908] Outpatient Busulfan (BU)/Cytoxan (CY)/ VP-16 and Autologous Stem Cell Transplant (ASCT) for Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD): Comprehensive Supportive Care Program Associated with Low Treatment Related Mortality and Hospital Utilization.[1909] When May Patients Be Considered Cured after Autografting for Hodgkin Lymphoma?
[1910] BEAM as a Frontline High Dose Chemotherapy Supported by Autologous PBSCT in Elderly Patients (≥60 Years) with Diffuse Large B-Cell Lymphoma (DLBCL): Comparison with Younger Cohort of Patients [1912] The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD. [1914] Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractoried, or High-Risk B-Cell NHL.Clinical Care: Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution of Transplantation II [1961] Changes in L-Selectin Expression by T Lymphocytes after Extracorporeal Photochemotherapy. [1963] Bone Marrow Reaction in Patients with Chronic GvHD – An Immunohistochemical Analysis of Microvessels and Lymphocytes. [1965] Incidence and Outcome of Non-CMV Viral Infections in 202 Consecutive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients. [1967] Long-Term Ultra-Low-Dose Acyclovir Against Varicella-Zoster Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation. [1969] The PTPN22 1858C/T Polymorphism Is Associated with the Development of Grade 3 to 4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning. [1971] Possible Involvement of γδ-T Cells in the Development of Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. [1973] Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoetic Stem Cell Transplants. [1975] Analysis of Predictive Power of Prednisone Dose at 3 Months of Treatment on CGVHD Prognosis. [1977] Elevated CD56dimCD16neg NK Cells on Day 28 after HCT: Role in Immunity Against Viral Infections or Residual Tumor Cells? [1979] Pre-Transplant Hypogammaglobulinemia Influences Survival after Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).
Clinical Care: Transplantation Regimen Toxicities and Engraftment I [1981] Genetic Polymorphisms of Gluthatione-S-Transferases in Two Different Populations of Fanconi Anaemia Patients. [1983] Recipient Genotype for the IL-10 -1064 Promoter Gene STR Polymorphism Influences the Risk of Graft Failure/Rejection after HLA Matched Allogeneic Hematopoietic Stem Cell Transplant in a Chimerism Mediated Fashion. [1985] Comorbidity Indexes and Allogeneic Stem Cell Transplantation (SCT). [1987] Validation of a Pretransplantation Assessment of Mortality (PAM) Score for Predicting Risk of Death in the First Two Years after Allogeneic Hematopoietic Cell Transplantation in a Tertiary Transplant Center. [1989] Obesity Does Not Impact Outcome in Patients with AML/MDS Undergoing Allogeneic Transplantation
[1990] Therapeutic Drug Monitoring (TDM) of IV Busulfan in Patients with Severe Obesity.
[1991] Transplant Outcome Is Not Affected by Body Mass Index (BMI) in Patients with Haematological Malignancies. [1993] Assessment of Individual Characteristics on the Pharmacokinetics of Oral Busulfan in Adults Patients Undergoing Hematopoietic Stem-Cell Transplantation.PM [1995] Intravenous Busulfan–Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML – An ALWP-EBMT Survey [1997] Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning in Patients with Relapsed or Refractory Acute Myeloid Leukemia – Results of a Phase I/II Trial. [1999] Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation. [2001] Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). [2003] Comparison of 200 cGy vs. 400 cGy Total Body Irradiation (TBI) When Used with Fludarabine for Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (RIC AHSCT). [2005] Dyskeratosis Congenita: Low Regimen-Related Toxicity Following Hematopoietic Cell Transplantation (HCT) Using a Reduced Intensity Conditioning Regimen. [2007] Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients. [2009] Impact of T-Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning Regimen.Clinical Results: Alternative Donor Transplantation-Umbilical Cord Blood Transplants [2011] Comparative Single-Institute Analysis of Cord Blood Transplantation from Unrelated Donors with Unrelated Bone Marrow or Related Peripheral Blood Stem-Cell Transplants in Elderly Patients with Hematologic Diseases after Reduced Intensity-Conditioning Regimen. [2013] Unrelated Cord Blood Transplantation Using Myeloablative Regimen for Acute Leukemia Patients Aged between 50 and 55 Years: Single Institutional Retrospective Comparison with Patients Less Than 50 Years of Age. [2015] CD34+ Viability Is a Critical Determinant of the Engraftment Potential of Umbilical Cord Blood (UCB) in Double Unit Transplantation. [2017] An International Multi-Institutional Study of Double Cord Blood Transplantation in a Racially Diverse Population.
[2018] Double Cord Blood Transplantation in Bone Marrow Failure Syndromes.
[2019] Outcomes in the Recent Seattle Cord Blood Experience: Low TRM and Relapse; High Mild Acute GVHD and CMV Reactivation. [2021] Unrelated Cord Blood Transplantation for Children with Juvenile Myelomonocytic Leukemia. [2023] Cord Blood Transplantation from Unrelated Donors for Children with Acute Lymphoblastic Leukemia in Japan: The Impact of Methotrexate on the Clinical Outcome. [2025] Cord Blood Transplantation from Unrelated Donors for Adults with Advanced Lymphoid Malignancies – A Eurocord-Netcord Group/EBMT-LWP Study. [2027] Unrelated Cord Blood Transplantation after Reduced Intensity Conditioning (RIC) in Adults with Hematological Malignancy. An EBMT-Eurocord-Netcord, Société Française de Greffe de Moelle et de Thérapie Cellulaire and University of Minnesota Collaborative Study. [2029] Cord Blood Transplantation after Non Myeloablative Conditioning (Minneapolis Protocol): Impact on Transplant Outcomes in 112 Adults with Hematologic Malignancy. A French Multicentric Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Eurocord. [2031] Monitoring for HLA Antibodies in Cord Blood Transplantation. [2033] “Age” of the Cord Blood (CB) Unit: Impact of Long-Term Cryopreservation and Storage on Transplant Outcome.
Experimental Transplantation: Pre-Clinical and Clinical Studies on GVHD/GVL
[2161] Therapeutic Effect of CXCR3-Expressing Regulatory T Cells on Liver and Intestinal Damages in a Murine Acute GVHD Model. [2163] Spectratype Analysis of In Vitro Donor Anti-Host T Cell Repertoire Responses Predict Those of In Vivo Post-BMT. [2165] Breast-Feeding Mediates Feto-Maternal Tolerance and Improves Outcome of Allogeneic Bone Marrow Transplantation.[2166] TH17 Cells Mediate Extensive Skin Pathology in Acute GVHD.
[2167] Killer Immunoglobulin-Like Receptor and NOD2/CARD15 Polymorphisms Independently Influence Survival after Allogeneic Hematopoietic Stem Cell Transplanation. [2169] Th2.rapa Cell Treatment of Established Murine Acute GVHD Is Abrogated by IL-2 Therapy and T Regulatory Cells. [2171] A Shift in the Intestinal Microflora towards Pro-Inflammatory Bacteria and Signaling Via Toll-Like-Receptor 2 Triggers Early Onset of Graft-Versus-Host Disease.[2172] Absence of CCR4 Enhances the Function of Expanded Regulatory T-Cells.
[2173] CD6-Depletion in the Dog Model: New Insights into Chimerism and Tolerance. [2175] Host Interferon gamma Production and STAT-1 Signalling Is Crucial for Minor Antigen Mediated Rejection of High Grade Lymphoma. [2177] Extracorporeal Photopheresis Diminishes Graft-Versus-Host-Disease and Modulates Dendritic Cell Cytokine Production.[2178] CD62L Is Not Critical for T Regulatory Cell-Mediated Protection from Lethal Acute GVHD.
[2179] STAT3 Signaling in Donor-Derived CD4+ T-Cells Plays a Critical Role in the Induction of Acute and Chronic GVHD in Murine Models of alloBMT.[2180] Loss of IFNγR1 Signaling on Donor Bone Marrow Abrogates GVHD but Maintains Immunocompetence
[2181] CD11b-Donor Dendritic Cells Elevate Donor T-Cell Production of Interferon-Gamma and Graft-Versus-Leukemia Activity in Allogeneic Bone Marrow Transplantation. [2183] Functional Characterisation of Alloreactive T-Cells Identifies CD25 and CD71 as the Optimal Targets for Allodepletion Strategies. [2185] Lymphopenia Promotes the Development of Graft-Versus-Host Disease upon Donor Leukocyte Infusion. [2187] Complete Clinical and Molecular Remissions Due to Very Effective GVL Reactions after Allogeneic Blood Stem Cell Transplantation for Mantle Cell Lymphoma in First or Second Remission.New Agents and Treatment Approaches in Non-Hodgkin Lymphoma [2556] A Phase I-II Study To Determine the Safety, Pharmacokinetics and Potential Efficacy of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 of a 28 Day Schedule in Patients with Non-Hodgkin's or Hodgkin's Lymphoma. [2558] A Phase I/II Trial of Radioimmunotherapy (RIT) with 90Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma (NHL). [2560] Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma. [2562] Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). [2564] Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma. [2566] Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). [2568] A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study. [2570] High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma with Prior Stem Cell Transplant. [2572] Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy. [2574] Vorinostat (Suberoylanilide Hydroxamic Acid) in Relapsed or Refractory Hodgkin Lymphoma: SWOG 0517. [2576] Arsenic Trioxide (As2O3) Mediated Cell Death in Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL): Investigation of Reactive Oxygen Species (ROS), Caspase, and MAP Kinase Signaling Pathways. [2578] Bortezomib, Rituximab, and Dexamethason (BORID) as Salvage Treatment in Relapsed/Refractory Mantle Cell Lymphoma: Sustained Disease Control in Patients Achieving a Complete Remission. [2580] IELSG Phase II Studies of Bortezomib in Malt Lymphomas.
[2581] Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies.
[2582] Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Provides Prolonged Safety and Clinical Benefit to Patients with Advanced Cutaneous T-Cell Lymphoma (CTCL).Non-Hodgkin Lymphoma: Biology-Indolent B Cell Non-Hodgkin Lymphoma [2602] Numbers of Lymphoma Associated Macrophages (LAMS) and Regulatory T-Cells (Tregs) in Follicular Lymphoma (FL) Patients (pts) Treated with and without Monoclonal Antibody (MoAb)-Containing Therapy Do Not Correlate with Overall Survival (OS): A Study from the Southwest Oncology Group (SWOG). [2604] Serum Evaluation of a Panel of 10 Cytokines in Patients with Follicular Lymphoma: High Serum Level of TGF-β Correlates with Good Prognosis, Independently of the FLIPI Score. [2606] Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMPP. [2608] Promoter Methylation of Multiple Genes in Diffuse Large Cell Lymphoma (DLCL), Follicular Lymphoma (FL) and Bening Follicular Hyperplasia (BFH). [2610] Developing a Multidimensional Prognostic Test for Follicular Lymphoma.
[2611] Grading Follicular Lymphoma: No Difference between 1, 2 and 3a, but 3b Is Something Else.
[2612] Correlates of Treatment Intensity for Initial Management of Follicular Lymphoma (FL) in the United States: Report from the National Lymphocare Study (NLCS). [2614] Majority of Transformed Lymphomas Have High SUVs on PET Scanning Similar to Diffuse Large B Cell Lymphoma (DLBCL). [2616] Multiplex Analysis of Serum Cytokine Levels in Waldenström Macroglobulinemia Patients. [2618] The Brain Transcription Factor OTX1 Is Activated in Specific Non-Hodgkin Lymphoma Subtypes and Normally Expressed in a Germinal Center-Restricted Small Subpopulation of CD138+ Plasmacell-Like Cells. [2620] High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories. [2622] Chemokine Receptor Expression Profile in the Model of Parotid MALT Lymphomagenesis: De Novo Expression of CXCR6. [2624] High Frequency of Loss of Heterozygosity Due to Uniparental Disomy or Allele Deletion of Ocular Adnexal MALT-Type Lymphoma. [2626] STAT5 Signaling Is Associated with the Outcome of Follicular and Mantle Cell Lymphoma Patients Treated with Immunochemotherapy.[2627] Hepatitis B and C Virus in Patients with Non-Hodgkin Lymphoma.
[2628] A Prospective Clinical Trial of a Novel Epstein-Barr Virus (EBV) PCR Panel in Patients with EBV Associated Malignancies. [2630] IgM+ B-Cells Lacking CD27 Expression Display Somatically Mutated Ig VH Genes and Define a New Memory Population.Follicular Lymphoma: Transformation [182] Genetic Reconstruction of Follicular Lymphoma Evolutions: Sµ Mutations Studies Suggest Two Progression Patterns, Early Direct or Late from FL “Stem Cells”.
[183] High Frequency of 1p36.32 Deletion or Loss of Heterozygosity in Follicular Lymphoma (FL).
[184] Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL). [186] Gene Expression Analysis of Follicular Lymphoma Provides a Potential Rationale for Histological Grading Revision.Lymphoma: Chemotherapy, excluding Pre-Clinical Models-Follicular and Mantle Cell Lymphoma [386] Effect of Rituximab and/or High-Dose Therapy with Autotransplant at Time of Relapse in Patients with Follicular Lymphoma. [388] European MCL Network: An Update on Current First Line Trials. [390] Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD – A New Standard in Therapy?
Clinical Results: Allogeneic Matched Related Donor Transplantation II
[481] Impact of the Donor Recipient Sex Combination in Hematopoietic Stem Cell Transplantation: H-Y as a Model for the Interaction between Major and Minor Histocompatibility Antigens. [483] Hepatitis – Associated Aplastic Anaemia: Epidemiology and Treatment Results Obtained in Europe. A Report of the EBMT Aplastic Anemia Working Party. [485] Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up.Lymphoma: Chemotherapy, excluding Pre-Clinical Models-Aggressive Lymphoma [518] High Survival Rate in Adult Burkitt's Lymphoma/Leukemia and Diffuse Large B-Cell Lymphoma with Mediastinal Involvement. Session Type: Oral Session - 01:45 PM [520] Central Nervous System (CNS) Relapse in Agressive Non-Hodgkin's Lymphoma; Does CNS Prophylaxis Work? Session Type: Oral Session - 02:15 PM [522] Secondary Malignancies after Treatment of Aggressive Non-Hodgkin Lymphoma: A GISL Cohort Study on 1259 Patients.
Tumor Immunotherapy: Cancer Vaccines and Adoptive Immunotherapy in the Context of Transplantation [578] Vaccination with DC/Multiple Myeloma Fusions in Conjunction with Stem Cell Transplantation.
[579] Targeted 'Off-the-Shelf' Tumor Immunotherapy Using Allogeneic T-Cell Precursors.
[580] Autologous Cytokine-Induced Killer Cells as Post-Transplant Cellular Immunotherapy. [582] Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, -2 and -3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.
Autologous Transplantation: Clinical Results
[602] Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.[603] Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.
[604] Molecular Markers Predicting Clinical Outcome in Patients with Intermediate-Risk Acute Myeloid Leukemia Receiving Autologous Stem Cell Transplantation. [606] Elevated Pretransplant Serum Ferritin in Autologous Stem Cell Transplant.Clinical Care: Transplantation Regimen Toxicities and Engraftment-Regimen-Related Toxicities [614] A Phase 3 Randomized, Historically-Controlled Clinical Trial Investigating the Use of Defibrotide in the Treatment of Severe Veno-Occlusive Disease Post-SCT: A Novel Approach to the Validation of a Promising New Drug for the Treatment of a Life Threatening Disease. [616] Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma. [618] Low Transplant-Related Mortality in Patients with Hematologic Malignancies Undergoing Umbilical Cord Blood Transplantation (UCBT) with Thiotepa (TT), Once-Daily Intravenous (IV) Busulfan (BU), Fludarabine (FLU) and Anti-Thymocyte Globulin (ATG).
Immunotherapy for Lymphoma, including Radio-Immunotherapy
[643] 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients. [645] Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma. [647] Anti-Idiotype Antibody Response after Vaccination Correlates with Better Overall Survival in Follicular Lymphoma.[2968] The Impact of NOD2/CARD15 and KIR Polymorphisms on the Incidence of Infectious Complications in allo-HSCT Recipients. [2970] Association of Fc Receptor-Like Protein Family with Chronic Graft-Versus-Host Disease. [2972] Rituximab (RTX) as Salvage Therapy for Refractory Chronic Graft-Versus-Host Disease (cGVHD). [2974] Cytomegalovirus (CMV) Reactivation after T-Cell Replete Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Correlates with Donor KIR Genotype. [2976] Phase I Clinical Trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher Doses of Donor Lymphocyte Infusions Depleted of Alloreactive Cells Using ATIR May Improve Outcome without Causing GVHD. [2978] In Vivo Expansion of CD4+ FOXP3+ Regulatory T Cells May Contribute To Control of Acute GvHD after HLA-Mismatched Alloanergized HSCT. [2980] Anti-Thymocyte Globulin Induces Higher Response Rates and Less Graft-Versus-Host Disease in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation. [2982] Rituximab Infusion after Allogeneic HCT Delays B Cell Reconstitution and Alloimmunity. [2984] Recovery of the NK Cells and Its Intending Clinical Roles after Unmanipulated Haploidentical Blood and Marrow Transplantation. [2986] DAAM2 Polymorphism and Allogeneic Hematopoietic Stem Cell Transplantation. [2988] NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy. [2990] Reduced Incidence of Acute Graft Versus Host Disease (GVHD) and Transplant-Related Mortality (TRM) with the Addition of Short-Course Mini-Dose Methotrexate (MTX) to Cyclosporine (CSA) as GVHD Prophylaxis Following Nonmyeloablative Hematopoietic Stem Cell Transplantation (NST). [2992] IL-7 along with Optimized CD3/CD28 Artificial APC Beads Promotes Ex Vivo Expansion of Cord Blood T Cells towards Adoptive Immunotherapy. [2994] Effect of T Cell Recovery on Overall Survival (OS) Following Pentostatin Conditioning for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).
Clinical Results: Allogeneic Matched Related Donor Transplantation II
[3026] A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. [3028] Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor. [3030] Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma. [3032] A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma. [3034] Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI). [3036] Allogeneic HSC Transplantation for Multiple Myeloma: A Single Institution Experience. [3038] Efficacy of Allogeneic Stem-Cell Transplantation for T/NK-Cell Lymphomas in Adults. [3040] Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma. [3042] Allogeneic Stem Cell Transplantation in Angioimmunoblastic T-Cell Lymphoma (AITL): A Retrospective Survey from the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). [3044] Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-Cell Lymphoma: Evidence of Graft-Versus-Lymphoma Effect. [3046] Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT). [3048] Impact of Infused Peripheral Blood Stem Cell Parameters (Total Nucleated Cells, CD34+ Cells, CD3+ Cells and CFU-GM) on Transplant Outcome after Reduced Intensity Allogeneic HSCT.
Hematologic Malignancies and Treatment Complications
[3312] Measuring the Ability of Primary-Care Physicians To Diagnose and Manage Patients with Hematologic Malignancies. [3314] Ongoing Strong Improvement in Treatment Outcomes for Patients Diagnosed with Non-Hodgkin Lymphoma from the 1990s to the Early 21st Century. [3316] Socio-Economic and Clinical Factors Are Associated with In-Hospital Mortality in Patients Admitted for Diffuse Large B-Cell Lymphoma. [3318] Development of Computer Based System To Aid Pathologists in Histological Grading of Follicular Lymphomas. [3320] Cost of 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Versus Cost of Standard Regimens for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma in Switzerland. [3322] Examining Decision Making Styles in Patients with Lymphoma and Multiple Myeloma Considering Autologous Stem Cell Transplantation. [3324] A Budget Impact Model Comparing Resource Utilization of Four Approved Therapies for Multiple Myeloma (MM) in the US. [3326] Multiple Myeloma in Manitoba: A Population Based Study. [3328] Cost-Effectiveness Analysis in Canada of Dasatinib Versus Imatinib for the Treatment of Chronic Myelogenous Leukemia in Patients with Imatinib Resistance. [3330] Predictive Value of the Psychosocial Assessment of Candidates for Transplantation (PACT) Scale in Allogeneic BMT. [3332] Utilization of Resources and Overall Outcome in Patients Undergoing Hematopoietic Stem Cell Transplantation Related to Psychosocial Factors as Measured by the Transplant Evaluation Rating Scale (TERS). [3334] Medical Costs Analysis for Antifungal Prophylaxis in Neutropenic Patients with Hematological Malignancies: A Systematic Review Analysis. [3336] Cost-Effectiveness of Posaconazole vs Fluconazole in the Prevention of Invasive Fungal Infections among Patients with Graft-Versus-Host Disease (GVHD) in the US. [3338] Resource Use and Costs Associated with Routine Management of Febrile Neutropenia in German Hospitals. [3340] Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.
Immunotherapy for Lymphoma, including Radio-Immunotherapy
[3408] Meta Analysis: Rituximab as Maintenance Therapy for Patients with Follicular Lymphoma. [3410] Serum Cytokine Levels Predict Time to Progression after Rituximab as Initial Therapy in Patients with Follicular Grade 1 Non-Hodgkin Lymphoma. [3412] Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan (Zevalin®) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A 'Real-Time' MBR RQ-PCR Analysis. [3414] Late-Onset Neutropenia in Rituximab-Treated Lymphoma Patients: Lymphocyte Subpopulation Imbalances, Bone Marrow Hematopoiesis and Immunohistology. [3416] FCgamma Receptor Polymorphisms Do Not Influence the Outcome of Treatment with Rituximab Followed by Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH). [3418] Complement Activation and Resistance within the Cerebrospinal Fluid Following Intraventricular Administration of Anti-CD20 in the Treatment of Recurrent CNS Lymphoma. [3420] Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT). [3422] Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin's Lymphoma Patients Enrolled in a Phase I Study. [3424] Support for a Possible "Vaccinal" Effect of Rituximab; Lymphoma Idiotype Specific T-Cell Responses in Follicular Lymphoma Patients Treated with Rituximab.05:00 PM[3425] Alemtuzumab in Patients with Advanced Mycosis Fungoides and Sezary Syndrome.
[3426] Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective “Dose”-Finding Study. [3428] Survival in Follicular Lymphoma: The Stanford Experience, 1960-2003.[3429] R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL). [3431] Final Analysis of Phase II Study of CHOP/CHOEP-14 Followed by Consolidation with Alemtuzumab in Untreated Aggressive T-Cell Lymphomas (DSHNHL 2003-1). [3433] Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome? [3435] Interstitial Lung Disease in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP-Based Chemotherapy Is Associated with the Use of Rituximab. [3437] Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03-39B. A GELA Study. [3439] Improved Survival of Intravascular Large B-Cell Lymphoma (IVLBCL) by Rituximab Containing Combination Chemotherapies. [3441] A Comprehensive Geriatric Assessment Is More Effective Than Clinical Judgement to Prospectively Identify Elderly Patients with Diffuse Large Cell Lymphoma Who Can Tolerate Full-Dose Anthracyclin-Based Treatment and Achieve the Same Outcome as Young Patients. [3443] Efficacy of Dose-Dense R-CHOP-14 Chemoimmunotherapy Plus Pegfilgrastim for First-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in Low Risk Patients: An Interim Analysis of an Open-Label Clinical Trial in Spain. On Behalf of GEL/TAMO (Spanish Group of Lymphoma). [3445] CHOP-R (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab) Compared to CPOP-R (Cyclophosphamide, Pixantrone, Vincristine, Prednisone, Rituxamib) in First-Line Therapy of Diffuse Large B Cell Lymphoma (DLBCL): An Interim Analysis. [3447] CD5 Expression Is a Predictive Factor for Poor Prognosis among Biomarkers in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus CHOP Therapy. [3449] Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial. [3451] Outcome of Limited-Stage Peripheral T-Cell Lymphoma: Results from the Nebraska Lymphoma Study Group. [3453] Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study. [3455] Serum-Soluble Interleukin-2 Receptor (sIL-2R) Is an Extremely Strong Prognostic Factor for Patients with Peripheral T-Cell Lymphoma, Unspecified (PTCL-U). [3457] HIV-Associated NK/T-Cell Lymphomas: A Review of 93 Cases.
Non-Hodgkin Lymphoma: Biology-T-Cell and B-Cell
[3563] Amplification at 7q22 Targets CDK6 in T-Cell Lymphoma. [3565] EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies. [3567] Array CGH Analysis of Nodal T-Cell Lymphomas: Identification of Genomic Alterations Specific to Angioimmunoblastic and Unspecified Subtypes, and Correlation with Transcriptomic Data. [3569] A Multicenter Clinicopathologic Experience of HTLV-1 ATLL: A Retrospective 15 Year Review Reveals Little Progress. [3571] Identification of Critical Phosporylation Sites within NPM-ALK That Regulate JUNB mRNA Translation. [3573] Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome. [3575] A Long-Term Study on Indolent Adult T-Cell Leukemia/Lymphoma (ATLL). [3577] Lack of Survival Improvement in Patients with Large Cell Lymphomas of T-Cell Phenotype: A SEER Analysis Comparing Outcomes According to Phenotype and Year of Diagnosis. [3579] Cause-Specific Mortality and Second Cancer Incidence after Non-Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study. [3581] CtBP1 Is a Novel and Essential Corepressor for BCL6 Autoregulation.[3582] Aberrant Hedgehog Signaling Represents a Novel Therapeutic Target in B Cell Lymphomas.
[3583] Clinical, Prognostic and Possible Therapeutic Relevance of Angiogenesis in Non-Hodgkin's Lymphoma. [3585] APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.[3586] Differences in the C13orf25 miRNA Cluster in Non-Hodgkin Lymphoma and Normal B-Cell Subtypes.
[3587] Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin's Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA). [3589] Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin's Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.[3590] Constitutive Chemokine Receptor Expression in B-Cell Non-Hodgkin's Lymphoma.
[3591] Galiximab Sensitizes Malignant Human B Cell Lines to Apoptosis by Chemotherapeutic Drugs.[3592] CMV-Associated Expansion of CD8+CD45RA+CD27- T-Cells in Patients with B-Cell Malignancies.
Immuno-Chemotherapy for Diffuse Large B Cell and Follicular Lymphoma
[787] Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone. [789] Dose-Dense Rituximab Improves Outcome of Elderly Patients with Poor-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). [791] BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial.